Latest Financial Management News

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

xReality Group Limited has reported its strongest quarter yet, with cash receipts soaring 87% year-on-year to $5.2 million, driven by robust growth in its Operator XR enterprise software and entertainment divisions.

TZ Limited reported a quarterly revenue shortfall in Q2 FY2025 due to delayed US projects but anticipates a strong rebound post-election and strategic growth through acquisition.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Brookside Energy Ltd delivered a standout quarter in Q4 2024, posting record production growth and a 667% jump in operating cash flow, while completing a major development project ahead of schedule and under budget.

IRIS Metals has completed key drilling programs at its South Dakota lithium projects and successfully raised $8 million, positioning itself to deliver its maiden mineral resource estimate for the Beecher Project in early 2025.

Focus Minerals Ltd. reported record ore processing at its Three Mile Hill plant and significant progress on the Bonnie Vale Underground Mine during the December 2024 quarter, supported by a solid cash position of $16.5 million.

Hawthorn Resources has completed a pivotal Pre-Feasibility Study for its Mt Bevan Magnetite project and strategically converted its equity stake into a royalty, positioning the company for future value capture amid evolving market dynamics.

High Peak Royalties has fully repaid its US$750,000 financing facility with Macquarie Bank, removing all associated securities and guarantees. The company signals confidence in its near-term liquidity and operational funding.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.